18:18 , Sep 7, 2018 |  BC Week In Review  |  Financial News

Adaptimmune raises $100M via registered direct offering

Adaptimmune Therapeutics plc (NASDAQ:ADAP) raised $100 million through the sale of 10 million ADSs at $10 in a registered direct offering to Matrix Capital Management, New Enterprise Associates and Syncona Ltd. (LSE:SYNC). The price is...
16:28 , Sep 5, 2018 |  BC Extra  |  Financial News

Adaptimmune raises $100M via registered direct offering

Adaptimmune Therapeutics plc (NASDAQ:ADAP) raised $100 million through the sale of 10 million ADSs at $10 in a registered direct offering to Matrix Capital Management, New Enterprise Associates and Syncona Ltd. (LSE:SYNC). The price is...
01:37 , Aug 10, 2018 |  BC Innovations  |  Finance

Super-sized ambitions

A trend toward super-sized initial financings is attracting a new set of deep-pocketed investors to the early stage space. These new players are making earlier commitments with hopes of guaranteeing larger ownership positions at an...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

GSK, 23andMe partner on target, drug discovery

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on July 25, when the pharma provided an R&D update, announced 2Q18...
23:14 , Jul 25, 2018 |  BC Extra  |  Company News

GSK's near-term R&D prospects include an ADC as it pivots to immunology

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) will focus near-term R&D on label expansions plus first-in-class antibody-drug conjugate (ADC) GSK2857916 for multiple myeloma. The news came on Wednesday, when the pharma provided an R&D update, announced 2Q18 earnings...
16:50 , Jun 8, 2018 |  BC Week In Review  |  Clinical News

Adaptimmune reports Phase I safety data for TCR therapy

Adaptimmune Therapeutics plc (NASDAQ:ADAP) reported safety data from eight evaluable patients receiving 90-100 million cells of its MAGE-A10 SPEAR T cell therapy in two open-label Phase I trials to treat cancer. The data were presented...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of investors...
19:34 , May 17, 2018 |  BC Innovations  |  Finance

Europe’s piece of the pie

With China’s rising infrastructure for life science innovation and the unabated growth of U.S. science, Europe has two cards to play that can help it compete globally: expertise in key core technologies and its centralized...
15:23 , Apr 13, 2018 |  BC Week In Review  |  Company News

Orchard gains GSK's rare disease gene therapy portfolio

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.). GSK will be eligible to receive undisclosed commercial milestones and royalties. The pharma will...
15:48 , Apr 12, 2018 |  BC Extra  |  Company News

Orchard gains GSK's rare disease gene therapy portfolio

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said it will divest its rare disease gene therapy portfolio, including Strimvelis, to Orchard Therapeutics Ltd. (London, U.K.). GSK will be eligible to receive undisclosed commercial milestones and royalties. The pharma will...